Plasma Apolipoprotein CI and CIII Levels Are Associated With Increased Plasma Triglyceride Levels and Decreased Fat Mass in Men With the Metabolic Syndrome
- Rachel L.M. van der Ham, MD1,
- Reza Alizadeh Dehnavi, MD1,
- Jimmy F.P. Berbée, PHD2,
- Hein Putter, PHD3,
- Albert de Roos, MD, PHD4,
- Johannes A. Romijn, MD, PHD2,
- Patrick C.N. Rensen, PHD2 and
- Jouke T. Tamsma, MD, PHD1
- 1Section of Vascular Medicine, Department of Endocrinology and Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands
- 2Department of Endocrinology and Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands
- 3Department of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands
- 4Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
- Corresponding author: Rachel van der Ham, r.l.m.van_der_ham{at}lumc.nl
Abstract
OBJECTIVE—To determine whether, in accordance with observations in mouse models, high concentrations of the lipoprotein lipase inhibitors apolipoprotein (Apo) CI and ApoCIII are associated with increased triglyceride concentrations and decreased fat mass in men with the metabolic syndrome.
RESEARCH DESIGN AND METHODS—Plasma ApoCI, ApoCIII, and triglyceride concentrations were measured in the postabsorptive state in 98 men with the metabolic syndrome. Subcutaneous and visceral fat areas were measured by 3T-magnetic resonance imaging.
RESULTS—Triglyceride concentrations were 49% higher, and the average visceral fat area was 26% lower (both P < 0.001), in subjects with high ApoCI and ApoCIII compared with low ApoCI and ApoCIII. Subjects with either high ApoCI or ApoCIII had 16% (P < 0.05) and 18% (P < 0.01) decreased visceral fat area, respectively.
CONCLUSIONS—High concentrations of ApoCI and ApoCIII are associated with increased triglycerides and decreased visceral fat mass in men with the metabolic syndrome. These findings translate mouse studies into human pathophysiology.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 3 October 2008.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted September 17, 2008.
- Received July 18, 2008.
- DIABETES CARE
